EIN Presswire: Pharmaceuticals Featured Press Releases

FRP Training Courses Slated for Houston and Frankfurt

Tue, 07 Feb 2012 16:11:40 +0000

/EINPresswire.com/ St. Louis, Missouri - February 7, 2012- The Materials Technology Institute (MTI) is sponsoring a two-day training program on Inspection of New FRP Equipment & Piping March 5-6 in Houston, Texas and a one-day session in Frankfurt, Germany March 26. These unique programs will provide a comprehensive overview of the areas that are of critical importance for evaluating the quality and conformance of new FRP equipment and piping.

The classroom sessions are intended for personnel who are professional inspectors, but have little or no background in FRP inspections. An engineering degree or certificate and/or experience in fabrication, repair, or inspection of FRP equipments are recommended prerequisites.

"While there are quite a few public courses, seminars, and training classes to help younger and less experienced Inspectors develop inspection competencies for metallic equipment, the same does not apply for fiberglass reinforced plastic (FRP) equipment," points out Hardin Wells, Sr. Advisor - Mechanical Tech Service at Albemarle Corporation and MTI Project Champion. "The membership of the Materials Technology Institute recognized the lack of similar training for FRP equipment. The MTI FRP Inspector training class is designed as a first step towards filling that void.

"Unlike metallic equipment, where the raw materials (plate, pipe, fittings) are homogeneous and built in accordance by others per longstanding industry standards, the FRP materials used for FRP equipment are very much non-homogeneous, and are created by the fabricator as the equipment is being produced," explains Wells. "These features create significantly greater inspection challenges than are present for metallic equipment, where the inspector must validate both the creation of the raw material alongside creation of the equipment."

Presenter and FRP inspection expert Juan Bustillos, Bustillos & Associates, LLC, will cover the following topics in the training sessions:

• FRP Materials - Resins, Reinforcements & Cure Systems
• FRP Manufacturing Methods Overview
• Manufacturing Specifics - Vessels & Piping
• Inspection & Testing
• Inspection Safety
• Applicable Codes & Standards
• Flaw Definitions - Descriptions of all common flaws
• FRP Flaws & Imperfections
• Dual Laminates (Frankfurt session only)

In addition to classroom training, attendees will receive a CD including all course materials and presentations. Upon completion of a comprehension test (Houston-only), attendees will also receive a certificate.

For more information or to register for the Houston event, contact Lori Elgin at lelgin@mti-global.org. For the Frankfurt session, contact Katherine Reinecke at kreinecke@mti-global.org. Please be aware that space for these sessions is limited.

About MTI: Founded in 1977, MTI is a unique, not-for-profit technology development organization representing private industry. It sponsors projects focused on both developing new technology and transferring existing knowledge to day-to-day practice. Practical, generic, nonproprietary studies are conducted on the selection, design, fabrication, testing, inspection, and performance of materials of construction used in the process industries. The scope of work includes evaluation of metallic, and nonmetallic materials, optimum design applications, fitness-for-service, mechanical integrity and life cycle determinations, and economic factors affecting performance of vessels, tanks, piping and other components. For more information, visit www.mti-global.org.

The NU-Life Cosmetics Cellulite Cream Questioned

Mon, 06 Feb 2012 19:22:09 +0000

Learn more about the NU-Life Cosmetics Cellulite Cream to see if it can help you.

/EINPresswire.com/ The NU-Life Cosmetics Thigh & Stomach Cream (cellulite cream) has drawn some negative responses within the Anti-aging community, there is some doubt as to the effectiveness of this breakthrough formula. Yes, cellulite is a nagging problem for a lot of people and it is not possible to "cure it". However, in theory cellulite can be reduced with a basic understanding of what it is and how it's formed.

Cellulite makes the thighs look bumpy, like orange peel because of fat pushing through the connective tissue under the skin. Cellulite is actually just like ordinary fat and becomes worse based on diet, lack of exercise and even hormonal imbalances. Reducing Cellulite is possible through a synergistic approach.

Vanessa Wilson of http://nulifecosmetics.com states, "On the blog You can get a copy of the 2012 Cellulite Report but here are 3 tips you can use to start reducing your cellulite right now."

"First, Drink water. Before you dismiss this, consider that water will improve skin elasticity and tightness. Second, intense resistance training. You must build muscle tissue. It doesn't mean get big muscle, but you need to increase the muscle tissue in order to get rid of fat. Third , use NU-Life Cosmetics Thigh & Stomach Cream".

Reducing Cellulite is possible and the aforementioned tips should not be partially applied. The effectiveness is in the synergism of each tip. "Some people will notice that even though they exercise frequently that they still have a cellulite problem. This is because you can't simply get rid of cellulite with exercise alone. You must change you diet and there are some supplements/products that work. Our Thigh & Stomach Cream is one product that will help reduce cellulite", said Wilson.

To get the FREE 2012 Cellulite Report visit the blog, http://nulifecosmetics.biz/cellulite-report-2/

When on the site take a look at the NU-Life Cosmetics entire line of products, Anti-Aging, Anti-Wrinkle, and the Cellulite Cream.

To learn more about NU-Life Cosmetics visit the following sections of the site:

http://nulifecosmetics.com
http://nulifecosmetics.biz

Also visit the facebook page and click the "Like" button for a FREE gift, http://facebook.com/nulifecosmetics

Media Contact:
Vanessa Wilson
nulifecosmetics.biz
2138143192
http://nulifecosmetics.com

The problem of steroid resistance in Asthma & COPD

Fri, 03 Feb 2012 06:50:21 +0000

/EINPresswire.com/ The similarities between the two conditions are juxtaposed with the subtle and important differences. Both pose unique and complex challenges, and these differences must be identified and isolated. As respiratory research continues to grow and prosper this event contributes further towards the understanding of how they can be dealt with in a successful and cost effective manner.

SMi present their 8th annual Asthma & COPD event to be held in London on Monday 16th & Tuesday 17th of April 2012. Building on the success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, this year will see an elite panel of speakers drawn for both industry and academia.

It also offers an ideal platform for those who have recently moved in to respiratory studies as well as established professionals. This is an opportunity to network with the leading protagonists in the field and to learn from their knowledge and experience as well as to share your own.

Key Speakers Include:

• Professor Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine
• Professor Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine
• Professor Wisia Wedzicha, Professor Respiratory Medicine, University College London
• Stefano Petruzzelli, Head, Respiratory Medicine Unit Corporate Clinical Development, Chiesi Farmaceutici
• Thys van der Molen, Professor of Primary Care Respiratory Medicine, University of Groningen University Medical Centre Groningen Centre for Medical Biomics
• Louise Donnelly, Reader in Respiratory Cell Biology, National Heart & Lung Institute

>>> To view the full programme and speakers click here

For more details contact Fateja Begum on: +44 (0) 20 7827 6184 or e-mail: fbegum@smi-online.co.uk

Molecular obesity, potency and other addictions in medicinal chemistry

Thu, 02 Feb 2012 14:06:34 +0000

/EINPresswire.com/ SMi's Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.

Leading speakers include:

Hit to lead with X-ray crystallography
• Leveraging hits with crystal structure insight
• Molecular design in team discovery
• Synchrotron beamline upgrades for pharma
Kenton Longenecker, Protein Crystallographer,

Structural Biology Department, Abbott.
Delivering impact from HTS - drawing on experiences from the Pfizer portfolio
This talk will provide specific examples in hit identification from HTS across the Pfizer portfolio, with a specific focus on:-
• Evolving approaches to compound file & subset screening
• Combining fragment screening & biophysics with small molecule HTS
• Use of chemogenomic libraries & pre-competitive screening collaborations to identify novel probes & targets
John Mathias, Head of Medicinal Chemistry -
Inflammation & Remodelling, Pfizer

Molecular obesity, potency and other addictions in medicinal chemistry
• Review of the developability issues associated with compounds of high lipophilicity
• Scientific and organisational reasons why we always tend towards such compounds
• Resisting the urge to use such compounds
Mike Hann, Director of Structural Biology Europe, GlaxoSmithKline

Key note speakers include:
• Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
• Mike Hann, Director of Structural Biology Europe, GSK
• Herbert Nar, Director Structural Research, Boehringer Ingelheim
• John Mathias, Head of the Pfizer HTS CoE, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
• José Duca, Head of CADD, Novartis Institutes for BioMedical Research, Inc.
• Gregor Macdonald, Head of Neuroscience Chemistry, Janssen Pharmaceuticals, Johnson & Johnson PRD

Click here to visit our website

Alternatively contact Fateja Begum on +44 (0) 20 7827 6184 or e-mail: fbegum@smi-online.co.uk

EIN News Announces Launch of Cephalon Daily Report

Mon, 30 Jan 2012 13:50:22 +0000

Washington, January 30, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company focused on political, business and industry news, has added Cephalon Daily Report to its Company Daily Reports news division.

For more news see:

- Cephalon Products News - http://cephalon.einnews.com/news/cephalon-products
- Cephalon Daily Report - http://cephalon.einnews.com/
- Company Daily Reports - http://world.einnews.com/publications/reports

About the publisher of Cephalon Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Maximise manufacturing efficiency and scale-ability for miniaturisation and bead milling

Fri, 27 Jan 2012 16:32:14 +0000

/EINPresswire.com/ With 2 months to go join SMi at their 9th annual Controlled Release conference to be held on the 28th & 29th March 2012 London. This must-attend event will once again lead the way in examining the latest developments in nanomedicine and featuring fresh presentations from companies including GlaxoSmithKline, Lundbeck, Merck Serono and Genzyme.

Controlled Release 2012 will allow delegates to meet and network with key decision makers from the top pharmaceutical companies, as well as discuss & debate current issues such as challenges in drug formulation for oral delivery - where are we and what are the prospects for the future, challenges and opportunities for delivering biologics to the CNS and solutions for dissolution testing of non-oral formulations.

Network with key presenters within the pharmaceutical industry that includes:

• Peter Timmins, Executive Director, Drug Products, Science and Technology, Bristol-Myers Squibb
• Mark Wilson, Director, Collaboration Management, GlaxoSmithkline
• Simon Holland, Director, Process Understanding & Control, GlaxoSmithKline
• Bernd Riebesehl, Principal Fellow, Parenteral Dosage Forms, Pharmaceutical and Analytical Development, Novartis
• Mostafa Nakach, Head of the Pharmaceutical Engineering Group, Sanofi-Aventis
• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Jonathan Brown, Senior Research Investigator, Bristol-Myers Squibb
• Tomas Landh, Director, Novo Nordisk
• Jan L. Powell, Director, Physiology, Shire HGT
• Lars Bauer, Senior Medical Director, Therapeutic Area CNS, UCB
• Karin Liltorp, Director, Preformulation, Lundbeck

Visit www.controlledrelease.co.uk for more information or to register your place. Alternatively, contact Ninica Hussain at Tel: +44 (0) 207 827 6115 or Email: nhussain@smi-online.co.uk

BrainStorm Cell Therapeutics (OTCBB:BCLI) Has Potentially Developed A Treatment For ALS

Wed, 25 Jan 2012 10:30:16 +0000

/EINPresswire.com/ Last week a U.S. company announced initial Phase I/II clinical trial results for ALS (Amyotrophic Lateral Sclerosis)

In the quest to find treatments for certain neurological diseases, BrainStorm is fast distinguishing itself as a leader in the field of regenerative medicine using stem cells through its unique platform called NurOwn™. The Company can process human mesenchymal stem cells, which are present in bone marrow and are capable of self-renewal as well as differentiation into many other tissues. What makes BrainStorm technology platform very attractive to Big Pharma partnering is the autologous nature of the bone marrow-derived stem cells. This will in turn drastically reduce the expected translation time to market. The value of a treatment for ALS in the U.S. and EU is estimated to be $4Billion. The potential applications for the NurOwn™ platform to treat disease is fast becoming a reality. In short, BrainStorm is leveraging a patient's own cells to heal itself of disease.

BrainStorm updated stakeholders recently with a review of the trial six months post transplantation. The Phase I/II clinical trial for ALS is being conducted at the prestigious Hadassah Medical Center in Jerusalem by renowned Professor Dimitrios Karussis, M.D., Ph.D. and a distinguished scientific team in its own right from BrainStorm headed by Professor Eldad Melamed. Patients have been transplanted with stem cells derived from their own bone marrow and treated with BrainStorm's NurOwn™ stem cell technology. The trial will include a total of 24 patients, 12 in an advanced stage of the disease and 12 in an early stage.

The staff at Stem Cell Media and www.InvestorStemCell.com has initiated broad investor awareness coverage after Dr. Dimitrios Karussis announced early indications of efficacy last week. Dr. Karussis said, "There have been no significant side effects in the initial patients we have treated with BrainStorm's NurOwn™ technology. In addition, even though we are conducting a safety trial, the early clinical follow up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power. I am very excited about the safety results, as well as these indications of efficacy, we are seeing. This may represent the biggest hope in this field of degenerative diseases, like ALS."

Sai Rosen, Director of Operations for iCELL, commented, "With all the doom and gloom as of late in the world, we see men and women committed to easing the suffering of millions through regenerative medicine using stem cells. Bravo to BrainStorm tireless efforts to find treatments for unmet medical needs!"

BrainStorm's ALS trial is coming to the United States sometime in 2012. After receiving Orphan Drug Designation for its NurOwn™ cell therapy for ALS in the US, BrainStorm is planning to carry out its Phase II clinical trials in the US. To that end, BrainStorm Cell Therapeutics is currently working with the Northeast ALS consortium to design a phase II trial in the United States and has signed a Memorandum of Understating with the Massachusetts General Hospital and the University of Massachusetts Medical School in anticipation of applying for FDA approval to begin ALS human clinical trials in the United States in the course of 2012. The University of Massachusetts Medical School team will be led by Professor Robert H. Brown, MD, DPHIL., and Chair of the Neurological Department at University of Massachusetts Medical School. Professor Brown is a leading expert in neuromuscular genetics and is world renowned for his expertise in ALS. Professor Merit Cudkowitz will lead the Massachusetts General Hospital team.

About BrainStorm (OTC.BB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury

About Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector. Investor Stem Cell is the only online forum dedicated to stem cell investors. Before investing make sure to speak with a licensed investment professional.

Media Contact:
Sai Rosen
Stem Cell Media, LLC
http://investorstemcell.com/

PR courtesy of Online PR Media: http://bit.ly/w4V2NC

Lab88's Irexis Adds Puncture Vine An Ingredient Recognized To Act As An Aphrodisiac

Tue, 24 Jan 2012 06:45:50 +0000

/EINPresswire.com/ Tribulus Terrestris or Puncture Vine is one of the active ingredients in Irexis and has been shown to be an effective sexual enhancement supplement according to recent studies.

Tribulus Terrestris or Puncture Vine is one of the active ingredients in Irexis and has been shown to be an effective sexual enhancement supplement according to recent studies.

Puncture Vine grows prolifically in the United States and different parts of the plant are used in many herbal supplements found on the market today. According to research conducted by Monson and Schoenstadt, the plant can be used to treat a variety of ailments from kidney problems, urinary tract infections and blood pressure.

In addition to its many restorative and anti-bacterial properties is its ability to supplement and enhance sexual urges in both men and women and according to the Alternative Health Guide, it is an effective treatment for male impotence.

Puncture Vine is an effective aphrodisiac because it has been shown to increase the amount of testosterone in the body, by as much as 50%. This may have an effect on hair growth in addition to improved sexual function.

Lab88's Irexis contains a natural extract of Tribulus Terrestris in addition to its other active ingredients, all of which work to improve erectile functions and enhance sexual satisfaction. Irexis is designed to increase confidence by helping to prevent premature ejaculation by striving for stronger and longer lasting erections.

Irexis also contains an extract of Yohimba, an alkaloid that acts as a stimulant and aphrodisiac and is known for its therapy for sexual dysfunction. Irexis also includes Muira Puama, oyster meat extract and Maca, all of which promote penile blood flow and enhance sperm development. By expanding the blood vessels in penile tissue, this unique set of ingredients assists in boosting sexual stamina and improving performance.

Other ingredients include Astralagus root, liquorice, nettle and L-Arginine HCI. Research has shown that the L- Arginine aims to improve the health of blood vessels and vascular circulation which directly impacts on penile growth during arousal as blood supply is unhindered. Sperm production is also improved.

Stocks ship within two days and each bottle contains a one month's supply of sixty tablets. Irexis carries a 30 day, 100% money back guarantee because of Lab88's confidence in their male sexual enhancement product. Lab88 is proud to announce a special introductory offer of a single bottle of Irexis for $59.99 and a two bottle pack with a bottle free is $129.99.

###

CONTACT:
Rich Fuchs
rich@lab88.com
888.look.nice
888.566.5642 Ext. 106
http://www.lab88.com/sexual-dysfunction/irexis.asp

About Lab88
Whether it's to get a better night's rest, lose weight, increase energy or rectify sexual impotence, detoxify the liver, kidney or colon, or deal with any of a half-a-dozen other quality-of-life issues, Lab88 betters the life of its patients and consumers each and every day. Visit their website at www.lab88.com.

PR courtesy of Online PR Media: http://bit.ly/x3GyD8

Gilead Sciences Daily Report Launched by EIN News

Mon, 23 Jan 2012 11:56:21 +0000

Washington, January 23, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Gilead Sciences Daily Report.

For more details see:

- Gilead Sciences & HIV News - http://gileadsciences.einnews.com/news/gilead-sciences-hiv
- Gilead Sciences Daily Report - http://gileadsciences.einnews.com/

About the publisher of Gilead Sciences Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

EIN News Launches Caraco Pharmaceutical Daily Report

Thu, 19 Jan 2012 13:54:52 +0000

Washington, January 19, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company since 1995, has announced the launch of Caraco Pharmaceutical Daily Report.

For more news see:

- Caraco Pharmaceutical Services News - http://caraco.einnews.com/news/caraco-pharmaceutical-services
- Caraco Pharmaceutical Daily Report - http://caraco.einnews.com/

About the publisher of Caraco Pharmaceutical Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Lab88 Reports Enhanced Sexual Satisfaction with Irexis

Thu, 19 Jan 2012 13:45:40 +0000

/EINPresswire.com/ Lab88's male sexual supplement, Irexis, was developed to improve erectile function and enhance sexual satisfaction through the scientific application of natural ingredients.

Irexis naturally controls impotence by harnessing sexual energy and increasing male confidence by aiding the prevention premature ejaculation. Developed to help improve the quality of erections, Irexis seeks to stop premature ejaculation.

Irexis contains Yohimba extract, which is an alkaloid that acts as a stimulant and aphrodisiac and as a remedy for sexual dysfunction. Irexis also includes Muira Puama, oyster meat extract and Maca, all of which promote penile blood flow and enhancer for sperm development. By expanding the blood vessels in penile tissue, this unique set of ingredients boosts sexual stamina and improves performance.

Oyster meat extract is packed full of the amino acid, Taurine, which is beneficial for prostrate and sexual health. Maca is a South American rootplant, which has been shown to improve sperm quality and heighten the libido. The indigenous peoples of the Andes have used it to increase testosterone production and provide stimulation to the sexual reproduction system for many years. Muira Puama is from Brazil and is known locally as 'potency wood' because of its reputation as an aphrodisiac.

Other ingredients include Astralagus root, liquorice, nettle and L-Arginine HCI. Research has shown that the L- Arginine improves the health of blood vessels and vascular circulation which directly impacts on penile growth during arousal as blood supply is unhindered. Sperm production has also been shown to have improvement.

Stocks ship within two days and each bottle contains a one month's supply of sixty tablets. Irexis carries a 30 day, 100% money back guarantee because of Lab88's confidence in their male enhancement supplement. A single bottle of Irexis retails for $59.99 and a two bottle pack with a bottle free is $129.99.

Men enjoy life better with Irexis!

###

CONTACT:
Rich Fuchs
rich@lab88.com
888.look.nice
888.566.5642 Ext. 106
http://www.lab88.com/sexual-dysfunction/irexis.asp

About Lab88
Whether it's to get a better night's rest, lose weight, increase energy or rectify sexual impotence, detoxify the liver, kidney or colon, or deal with any of a half-a-dozen other quality-of-life issues, Lab88 betters the life of its patients and consumers each and every day. Visit their website at www.lab88.com.

PR courtesy of Online PR Media: http://bit.ly/wiZ4TO

Irexis' Ingredient Zinc Shown Necessary for Male Testosterone Health

Wed, 18 Jan 2012 07:57:09 +0000

/EINPresswire.com/ Irexis Male Enhancement Supplement Packed with Zinc for Men's Sexual Health

As men age, their sex drive may decrease dramatically. Kids, family and work are demanding aspects of a man's life, which can leave little time for investing time in a proper diet and exercise routine. This down-and-out mood can lead to decreased sex drive and once that happens, and help may be needed to get out of that slump. Irexis is the male enhancement pill packed with zinc, one of the prime ingredients for a healthy male libido. Irexis is safe and simple to take and is the answer for many men who need to jumpstart their stamina and libido once again.

Irexis is available online without a prescription. There's no need to find a doctor willing to give you the sometimes embarrassing prescription an erectile dysfunction pill. This is a male enhancement pill that's readily available and ready to spring into action whenever you are. With Irexis, men experience prolonged sexual sessions due to increased stamina. Men feel "in the mood" know they can confidently take charge of a situation and follow through. No more waiting around for things to happen. With Irexis, mood is sure to improve and desire is restored.

Irexis isn't magic, but it's packed with zinc, a key vitamin that makes a man crave intimacy. Zinc is required for basic male function, so adding an extra dose makes a man ready for sexual activity. Zinc is required for manufacturing testosterone and can also help regulate emotional problems such as depression. Irexis is not a cure for any illness, but it can provide that extra boost and supplement needed to help a man enjoy the moment and seize back his life. Zinc has also been known to fight infections and inflammation in the prostate gland. For males hoping to procreate, zinc is essential for helping sperm motility. It's no wonder this mineral is doing amazing things for men.

A single pack of Irexis is available for $59.99. The more you buy, the more you save. Check out the various package deals and options for Irexis by visiting http://www.lab88.com/sexual-dysfunction/irexis.asp.

###

CONTACT:
Rich Fuchs
rich@lab88.com
888.look.nice
888.566.5642 Ext. 106
http://www.lab88.com/sexual-dysfunction/irexis.asp

About Lab88
Whether it's to get a better night's rest, lose weight, increase energy or rectify sexual impotence, detoxify the liver, kidney or colon, or deal with any of a half-a-dozen other quality-of-life issues, Lab88 betters the life of its patients and consumers each and every day. Visit their website at www.lab88.com.

PR courtesy of Online PR Media: http://bit.ly/AAVwCg

TCT Receives Patent on Therapeutic Monoclonal Antibody Targeting Pancreatic Cancer

Tue, 17 Jan 2012 14:08:52 +0000

/EINPresswire.com/ SANTA ROSA, CA, (1/18/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its anti-CEACAM6 product received the U.S. Designation of Patent Number 8,038,996. The patent claims allow for a method of treating various types of cancer using an anti-CEACAM6 monoclonal antibody that induces apoptosis in cancer cells.

"We designed a monoclonal antibody that binds to CEACAM protein over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung ovarian cancers and certain childhood leukemias." stated Daruka Mahadevan MD, Ph.D., Chief Scientific Officer of TCT. "It is a highly specific monoclonal antibody designed to disrupt CEACAM6 function and was tailored for a superior safety profile. There is an unmet need for effective treatments of pancreatic cancer, as it is uniformly lethal and new treatment paradigms are urgently needed."

The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.

In 2010, there were over 40,000 pancreatic cancer cases, of which there were over 39,300 deaths, providing a dismal prognosis. This is attributable to a lack of early diagnosis and effective treatments. Most patients present with unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDA), with a median overall survival of 12 and 6 months respectively.

For more information on Targeted Cancer Therapeutics LLC and its products,
Email info@targetedcancer.com or visit www.targetedcancer.com

About Targeted Cancer Therapeutics (TCT)

Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.

Contact Information

William Mulert
President
(707) 477-7022
bmulert@targetedcancer.com

Geron Corporation Daily Report Launched by EIN News

Mon, 16 Jan 2012 12:14:24 +0000

Washington, January 16, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Geron Corporation Daily Report.

For more details see:

- Geron Biotechnology News - http://geron.einnews.com/news/geron-biotechnology
- Geron Corporation Daily Report - http://geron.einnews.com/

About the publisher of Geron Corporation Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com

Genzyme Daily Report Launched by EIN News

Fri, 13 Jan 2012 12:23:18 +0000

Washington, January 13, 2012 /EINPresswire.com/ EIN News, a leading media monitoring company published by the IPD Group, has announced the launch of Genzyme Daily Report.

For more details see:

- Genzyme Genetics News - http://genzyme.einnews.com/news/genzyme-genetics
- Genzyme Daily Report - http://genzyme.einnews.com/

About the publisher of Genzyme Daily Report, EIN News (http://www.einnews.com/)

EIN News has developed one of the world's leading real time news indexing services. Its systems continuously scan the web, indexing news from thousands of worldwide sources. The data is then filtered according to specific needs, and the processes are supervised by a team of professional news editors.

Thousands of industry, government and private institutions rely on EIN News for their media monitoring needs. Combining both intelligent search technologies and the human element, EIN News delivers the most efficient, yet personalized media monitoring, news aggregation and syndication services on the market.

EIN News is positioned as the leading news index on the planet.

For more information about EIN News:

David Rothstein
Chief Executive Officer
EIN News (an IPD Group Service)
http://www.einnews.com/contact
http://www.einnews.com